BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hodges CB, Maxwell H, Beattie TJ, Murphy AV, Jindal RM. Use of rapamycin in a transplant patient who developed cyclosporin neurotoxicity. Pediatr Nephrol. 2001;16:777-778. [PMID: 11605780 DOI: 10.1007/s004670100662] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Bates D, Burak KW, Coffin CS, Ying T, Enns EM. Phenytoin-induced reduction in sirolimus levels. Can J Hosp Pharm 2011;64:271-4. [PMID: 22479070 DOI: 10.4212/cjhp.v64i4.1040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Fridell JA, Jain AKB, Patel K, Virji M, Rao KN, Fung JJ, Venkataramanan R. Phenytoin Decreases the Blood Concentrations of Sirolimus in a Liver Transplant Recipient: A Case Report: . Therapeutic Drug Monitoring 2003;25:117-9. [DOI: 10.1097/00007691-200302000-00019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
3 Daoud D, Scheld HH, Speckmann EJ, Gorji A. Rapamycin: brain excitability studied in vitro. Epilepsia 2007;48:834-6. [PMID: 17284292 DOI: 10.1111/j.1528-1167.2006.00976.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]
4 Neff GW, Montalbano M, Tzakis AG. Ten years of sirolimus therapy in orthotopic liver transplant recipients. Transplant Proc. 2003;35:209S-216S. [PMID: 12742498 DOI: 10.1016/s0041-1345(03)00217-3] [Cited by in Crossref: 53] [Cited by in F6Publishing: 9] [Article Influence: 2.9] [Reference Citation Analysis]
5 Oellerich M, Armstrong VW, Streit F, Weber L, Tönshoff B. Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients. Clin Biochem 2004;37:424-8. [PMID: 15183289 DOI: 10.1016/j.clinbiochem.2004.04.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
6 Mour G, Wu C. Neurologic Complications After Kidney Transplantation. Seminars in Nephrology 2015;35:323-34. [DOI: 10.1016/j.semnephrol.2015.06.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
7 Filler G, Womiloju T, Feber J, Lepage N, Christians U. Adding Sirolimus to Tacrolimus-Based Immunosuppression in Pediatric Renal Transplant Recipients Reduces Tacrolimus Exposure. Am J Transplant 2005;5:2005-10. [DOI: 10.1111/j.1600-6143.2005.00963.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
8 Formea CM, Evans CG, Karlix JL. Altered Cytochrome P450 Metabolism of Calcineurin Inhibitors: Case Report and Review of the Literature. Pharmacotherapy 2005;25:1021-9. [DOI: 10.1592/phco.2005.25.7.1021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
9 Filler G, Bendrick-peart J, Strom T, Zhang YL, Johnson G, Christians U. Characterization of sirolimus metabolites in pediatric solid organ transplant recipients. Pediatric Transplantation 2009;13:44-53. [DOI: 10.1111/j.1399-3046.2008.00956.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
10 Lisik W, Kahan BD. Proliferation signal inhibitors: chemical, biologic, and clinical properties. Transplantation Reviews 2005;19:186-212. [DOI: 10.1016/j.trre.2005.11.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]